Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Caine + Zinc Subgallate is a combination rectal suppository developed by Jinzhou Jiutai Pharmaceutical for the treatment of anal fissures. The formulation combines a local anesthetic (typically benzocaine) with zinc subgallate, an astringent agent. The anesthetic component acts by blocking voltage-gated sodium channels on peripheral nerve endings, providing rapid relief from pain, itching, and discomfort associated with anal fissures. Zinc subgallate serves as an astringent and mild antiseptic, promoting the contraction of the anal mucosa, reducing inflammation, and facilitating the healing of the fissure. The drug has been investigated in Phase II clinical trials in China to evaluate its efficacy and safety compared to placebo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound caine + zinc subgallate.